What topics does this cannabis study cover?

This study covers research on: Addiction.

Where was this research published?

Published in Journal of insurance medicine (New York, N.Y.) on June 15, 2026.

Addiction

Rethinking smoker definitions in the age of alternative nicotine products

The Smoking Dilemma: A Technical Deep Dive.

Journal of insurance medicine (New York, N.Y.) • June 15, 2026 • Review • Moderately Relevant

🤖

AI Summary

This paper examines how evolving nicotine consumption patterns—including the rise of e-cigarettes and oral nicotine pouches—have challenged traditional definitions of "smokers" used in clinical and insurance settings. The research highlights a critical disconnect: while clinical definitions focus on health outcomes and are nuanced, insurance classifications remain binary and time-based, often defining smokers as anyone using nicotine products in the past 12 months. This outdated approach fails to account for the significant risk differences between combustible tobacco and non-combustible alternatives.

The authors argue that as cannabis legislation expands alongside growing alternative nicotine product use, insurers and healthcare providers need more sophisticated risk assessment frameworks. While combustible tobacco remains the highest-risk exposure, evidence suggests non-combustible nicotine products occupy a medium-risk category with documented early cardiovascular and metabolic effects, particularly concerning given their popularity among younger populations. The paper calls for enhanced underwriting practices including better product-type disclosure, improved verification strategies, and risk-based pricing that more accurately reflect actual exposure levels rather than relying on outdated categorical definitions.

This work is relevant to cannabis research primarily for its implications on how evolving consumption methods—similar to cannabis flower versus vaping versus edibles—require updated regulatory and risk assessment frameworks. The paper demonstrates why traditional categorical definitions fail to capture the heterogeneous risk profiles of different product delivery methods, a principle directly applicable to cannabis policy and insurance considerations as cannabis markets mature.

📄 Original Abstract

Traditional cigarette smoking has declined markedly over recent decades due to increased health awareness, regulatory action, and public health campaigns. At the same time, alternative nicotine products, particularly e-cigarettes and oral nicotine pouches, have gained popularity, especially in the United States and Europe and among younger populations. While cigarettes remain the most widely used tobacco product globally, tobacco and nicotine consumption now spans a broad range of combustible and non-combustible products, with smokeless tobacco predominating in some regions. Definitions of a "smoker" vary significantly between clinical practice and insurance medicine. Clinical definitions are nuanced and health-focused, whereas insurance classifications are typically binary and time-bound, often defining a smoker as anyone who has used a nicotine-containing product within the past 12 months. The growing use of alternative nicotine products, alongside evolving cannabis legislation, has exposed limitations in traditional definitions when it comes to accurately capturing associated risk. The expansion of alternative nicotine products challenges traditional smoker classifications used in insurance underwriting. While combustible tobacco remains the highest risk exposure, growing evidence supports the existence of a heterogeneous medium risk group associated with nicotine, noncombustible products. Although generally lower risk than cigarettes, these products are not risk-free, particularly considering early cardiovascular and metabolic effects, dual or poly-use patterns, and growing uptake at younger ages. For insurers, this evolving landscape highlights the benefit of a more nuanced underwriting approach, including enhanced disclosure of product type and use patterns, improved verification strategies, and potential pricing differentiation that better aligns risk with exposure.